Pfizer launches next-gen vaccine for pneumococcal disease

Pfizer has introduced its 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India, offering protection against 20 serotypes responsible for a majority of pneumococcal diseases. This single-dose vaccine provides timely and proactive protection for all adults, including those with chronic conditions, potentially eliminating the need for a second dose.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T8l6hCc
via IFTTT